NEW YORK – Trovagene has begun enrolling patients into the Phase Ib/II trial of onvansertib evaluating the investigational PLK1 inhibitor as a treatment for KRAS-mutated metastatic colorectal cancer.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.